Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...

HIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

The common belief that HIV affects only those deemed perverted or sinful discourages many from seeking screening as they fear ...

An event in Palm Springs will feature experts discussing updates in HIV research, as well as those living with HIV sharing ...

Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...

"It is crucial that Dr. Mezher retracts the incorrect claims from his TikTok." The post Viral Pic Of Bloody Toilet Paper ...

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...

Young people living with HIV play a critical role in the fight against AIDS in communities. They offer support and share ...

Twice-a-year-PReP will only fulfill its potential if Medicaid takes decisive action to ensure it is accessible to the ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...